Free Trial

Revolution Medicines (RVMD) Competitors

Revolution Medicines logo
$37.00 -0.19 (-0.51%)
Closing price 03:57 PM Eastern
Extended Trading
$37.39 +0.39 (+1.05%)
As of 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RVMD vs. ONC, BNTX, TEVA, SMMT, ITCI, GMAB, RDY, ASND, VTRS, and QGEN

Should you be buying Revolution Medicines stock or one of its competitors? The main competitors of Revolution Medicines include BeOne Medicines (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry.

Revolution Medicines vs. Its Competitors

BeOne Medicines (NASDAQ:ONC) and Revolution Medicines (NASDAQ:RVMD) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

BeOne Medicines has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500. Comparatively, Revolution Medicines has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500.

Revolution Medicines has lower revenue, but higher earnings than BeOne Medicines. BeOne Medicines is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BeOne Medicines$4.18B6.44-$644.79M-$3.72-65.99
Revolution Medicines$11.58M595.16-$600.09M-$4.00-9.25

48.5% of BeOne Medicines shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 6.6% of BeOne Medicines shares are held by insiders. Comparatively, 8.2% of Revolution Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Revolution Medicines has a net margin of 0.00% compared to BeOne Medicines' net margin of -9.40%. BeOne Medicines' return on equity of -7.55% beat Revolution Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
BeOne Medicines-9.40% -7.55% -4.42%
Revolution Medicines N/A -37.06%-32.84%

BeOne Medicines presently has a consensus price target of $320.67, suggesting a potential upside of 30.62%. Revolution Medicines has a consensus price target of $67.58, suggesting a potential upside of 82.66%. Given Revolution Medicines' higher probable upside, analysts plainly believe Revolution Medicines is more favorable than BeOne Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BeOne Medicines
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Revolution Medicines
0 Sell rating(s)
0 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Revolution Medicines had 1 more articles in the media than BeOne Medicines. MarketBeat recorded 12 mentions for Revolution Medicines and 11 mentions for BeOne Medicines. Revolution Medicines' average media sentiment score of 0.80 beat BeOne Medicines' score of 0.63 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BeOne Medicines
2 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Revolution Medicines
4 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Revolution Medicines beats BeOne Medicines on 11 of the 15 factors compared between the two stocks.

Get Revolution Medicines News Delivered to You Automatically

Sign up to receive the latest news and ratings for RVMD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RVMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RVMD vs. The Competition

MetricRevolution MedicinesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$6.93B$2.91B$5.54B$8.95B
Dividend YieldN/A2.42%5.38%4.08%
P/E Ratio-9.2521.4227.3820.03
Price / Sales595.16285.81422.31120.16
Price / CashN/A41.9536.6357.47
Price / Book2.757.518.085.67
Net Income-$600.09M-$55.05M$3.16B$248.47M
7 Day Performance-1.28%3.16%2.12%2.90%
1 Month Performance-8.82%5.92%4.43%5.75%
1 Year Performance0.22%5.82%35.62%21.36%

Revolution Medicines Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RVMD
Revolution Medicines
4.5755 of 5 stars
$37.00
-0.5%
$67.58
+82.7%
-0.5%$6.93B$11.58M-9.25250Analyst Revision
ONC
BeOne Medicines
3.574 of 5 stars
$257.51
+4.2%
$319.00
+23.9%
N/A$28.22B$3.81B-69.2211,000Gap Up
BNTX
BioNTech
2.5573 of 5 stars
$103.01
-3.3%
$137.86
+33.8%
+37.5%$24.76B$2.98B-30.306,772Gap Down
TEVA
Teva Pharmaceutical Industries
4.2244 of 5 stars
$16.96
+0.1%
$24.44
+44.1%
+3.0%$19.45B$16.54B-14.7536,830
SMMT
Summit Therapeutics
2.6871 of 5 stars
$20.39
-0.8%
$35.09
+72.1%
+200.0%$15.14B$700K-59.97110Trending News
Analyst Forecast
Options Volume
Trading Halted
ITCI
Intra-Cellular Therapies
0.9954 of 5 stars
$131.87
flat
$109.70
-16.8%
N/A$14.05B$680.50M-151.57560
GMAB
Genmab A/S
3.596 of 5 stars
$20.68
-2.3%
$39.17
+89.4%
-17.9%$13.26B$3.12B11.752,682High Trading Volume
RDY
Dr. Reddy's Laboratories
2.8525 of 5 stars
$15.31
+0.5%
$16.95
+10.7%
-2.3%$12.78B$3.81B23.2027,811
ASND
Ascendis Pharma A/S
3.5544 of 5 stars
$175.78
-0.6%
$220.67
+25.5%
+27.0%$10.75B$393.54M-27.991,017Analyst Forecast
VTRS
Viatris
3.8137 of 5 stars
$8.85
-0.2%
$10.40
+17.5%
-10.5%$10.39B$14.74B-2.7932,000
QGEN
Qiagen
3.9211 of 5 stars
$46.72
-0.1%
$47.74
+2.2%
+22.8%$10.39B$2.00B117.145,765Dividend Announcement

Related Companies and Tools


This page (NASDAQ:RVMD) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners